These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36929625)

  • 1. Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.
    Bauer RN; Teterina A; Shivram H; McBride J; Rosenberger CM; Cai F; Bao M; Tsai L; Gordon O; Lee IT; Wallin JJ; Porter D; Juneja K; Camus G; Rosas IO; Wildum S
    Clin Transl Sci; 2023 Jun; 16(6):1049-1062. PubMed ID: 36929625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
    To KK; Tsang OT; Leung WS; Tam AR; Wu TC; Lung DC; Yip CC; Cai JP; Chan JM; Chik TS; Lau DP; Choi CY; Chen LL; Chan WM; Chan KH; Ip JD; Ng AC; Poon RW; Luo CT; Cheng VC; Chan JF; Hung IF; Chen Z; Chen H; Yuen KY
    Lancet Infect Dis; 2020 May; 20(5):565-574. PubMed ID: 32213337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
    Tom J; Bao M; Tsai L; Qamra A; Summers D; Carrasco-Triguero M; McBride J; Rosenberger CM; Lin CJF; Stubbings W; Blyth KG; Carratalà J; François B; Benfield T; Haslem D; Bonfanti P; van der Leest CH; Rohatgi N; Wiese L; Luyt CE; Kheradmand F; Rosas IO; Cai F
    Crit Care Med; 2022 Mar; 50(3):398-409. PubMed ID: 34612846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
    Hooper AT; Somersan-Karakaya S; McCarthy SE; Mylonakis E; Ali S; Mei J; Bhore R; Mahmood A; Geba GP; Dakin P; Weinreich DM; Yancopoulos GD; Herman GA; Hamilton JD;
    mBio; 2022 Dec; 13(6):e0169922. PubMed ID: 36255239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).
    Rosas IO; Bräu N; Waters M; Go RC; Malhotra A; Hunter BD; Bhagani S; Skiest D; Savic S; Douglas IS; Garcia-Diaz J; Aziz MS; Cooper N; Youngstein T; Sorbo LD; Zerda DJ; Ustianowski A; Gracian AC; Blyth KG; Carratalà J; François B; Benfield T; Haslem D; Bonfanti P; van der Leest CH; Rohatgi N; Wiese L; Luyt CE; Bauer RN; Cai F; Lee IT; Matharu B; Metcalf L; Wildum S; Graham E; Tsai L; Bao M
    EClinicalMedicine; 2022 May; 47():101409. PubMed ID: 35475258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG Antibodies, SARS-CoV-2 Load, and Prognostic Indicators in Patients with Severe and Mild COVID-19 in Japan.
    Kashiwagi K; Maeda T; Yoshizawa S; Sato T; Aoki K; Ishii Y; Tateda K
    J Nippon Med Sch; 2021 Sep; 88(4):380-383. PubMed ID: 33250476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between viral load, infection-to-delivery interval and mother-to-child transfer of anti-SARS-CoV-2 antibodies.
    Poon LC; Leung BW; Ma T; Yu FNY; Kong CW; Lo TK; So PL; Leung WC; Shu W; Cheung KW; Moungmaithong S; Wang CC
    Ultrasound Obstet Gynecol; 2021 Jun; 57(6):974-978. PubMed ID: 33798280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time series analysis revealed prognostic value of continuous nasopharyngeal SARS-CoV-2 nucleic acid quantification for COVID-19: A retrospective study of >3000 COVID-19 patients from 2 centers.
    Wu Z; Yang C; Shen Y; Zhang Q; Tang X; Wang D; Xu Y; Cao G; Song X; Ma Y; Fan H; Lu H; Li Y; Li X; Shen Y; Zhang C; Zhu M; Teng X; Du Y; Guan M
    Clin Chim Acta; 2023 Feb; 540():117227. PubMed ID: 36640930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019.
    Magleby R; Westblade LF; Trzebucki A; Simon MS; Rajan M; Park J; Goyal P; Safford MM; Satlin MJ
    Clin Infect Dis; 2021 Dec; 73(11):e4197-e4205. PubMed ID: 32603425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial.
    Boyapati A; Wipperman MF; Ehmann PJ; Hamon S; Lederer DJ; Waldron A; Flanagan JJ; Karayusuf E; Bhore R; Nivens MC; Hamilton JD; Sumner G; Sivapalasingam S
    J Infect Dis; 2021 Dec; 224(11):1830-1838. PubMed ID: 34496013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
    Somersan-Karakaya S; Mylonakis E; Menon VP; Wells JC; Ali S; Sivapalasingam S; Sun Y; Bhore R; Mei J; Miller J; Cupelli L; Forleo-Neto E; Hooper AT; Hamilton JD; Pan C; Pham V; Zhao Y; Hosain R; Mahmood A; Davis JD; Turner KC; Kim Y; Cook A; Kowal B; Soo Y; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    J Infect Dis; 2022 Dec; 227(1):23-34. PubMed ID: 35895508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
    Sims JT; Poorbaugh J; Chang CY; Holzer TR; Zhang L; Engle SM; Beasley S; Doman TN; Naughton L; Higgs RE; Kallewaard N; Benschop RJ
    J Transl Med; 2022 Mar; 20(1):134. PubMed ID: 35303909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.